Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of thyroid beta-agonist

A dose, adrenal brain technology, applied in the field of treatment of X-linked adrenoleukodystrophy, can solve the problem of limited treatment options for X-ALD

Pending Publication Date: 2019-09-06
VIKING THERAPEUTICS INC +1
View PDF22 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Treatment options for X-ALD are limited as there is no cure and no approved therapies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of thyroid beta-agonist
  • Application of thyroid beta-agonist
  • Application of thyroid beta-agonist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0253] Example 1 - Evaluation of different treatment doses

[0254] Two different X-ALD fibroblast cell lines were incubated in duplicate with the four compounds at the three doses as indicated in Table 3.

[0255] table 3

[0256] compound Low middle high 2 100nM 1μM 10μM 4 100nM 1μM 10μM 1 1μM 10μM 100μM 3 1μM 10μM 100μM

[0257] Two X-ALD cell lines incubated with 100 μM of 1 and 3 died within 24 hours. This strongly suggests that 1 and 3 are toxic at 100 μM. After 72 hours, cells that had received 0.1 μM, 1 μM or 10 μM of 2 or 4, or 0.1 μM or 10 μM of 1 or 3 appeared healthy as judged by their proliferation and morphology.

[0258] After 72h, cells were harvested and mRNA was isolated for QPCR analysis. Such as figure 1 The effect of compounds on ABCD2 expression was compared to ABCD2 expression levels in untreated (DMSO) cell lines as shown in . For all 4 compounds tested, 10 μM was the most effective. A...

Embodiment 2

[0259] Example 2 - Evaluation after prolonged culture

[0260] Four X-ALD cell lines were incubated with four Compound 1, Compound 2, Compound 3 and Compound 4 at 10 μM. The effect of treatment on ABCD2 expression was analyzed at day 3 and day 10. For the 10-day incubation, refresh tissue culture medium and compounds on days 3 and 6.

[0261] Days 3, 6, and 10: All cells appeared healthy, proliferation was normal, and morphology was normal. No abnormality noted. After 3 days, cells were harvested and mRNA was isolated for QPCR analysis. After 10 days, cells were harvested and mRNA was isolated for QPCR analysis. For all samples, cDNA synthesis and QPCR were done on the same day.

[0262] Such as figure 2 The effect of compound treatment on ABCD2 expression was compared to ABCD2 expression levels in untreated (DMSO) cell lines at days 3 and 10, as shown in . Prolonged exposure resulted in comparable effects on ABCD2 induction.

Embodiment 3

[0263] Example 3 - 10-day treatment of VLCFA de novo synthesis

[0264]Five different X-ALD cell lines were incubated with 10 μM of compound 1, compound 2, compound 3 and compound 4, 5 mM 4PBA (sodium 4-phenylbutyrate) or 0.1 μM sobetirome for 6 days. On day 6, 30 μM D3C22:0 was added to assess the effect of treatment on β-oxidation and D3C26:0 de novo synthesis. 6 untreated control cells were included as well as 5 different untreated X-ALD cells to allow assessment of treatment effects. The total consisted of 41 experiments.

[0265] Such as Figure 4 As shown in , in untreated X-ALD cells, β-oxidation capacity was reduced by ~80%, and de novo synthesis of C26:0 was increased by ~4-fold. The positive control (4PBA) restored β-oxidation to -50% of control and normalized VLCFA synthesis to near normal levels. The positive control (sobetirome) did not show any beneficial effect on VLCFA β-oxidation or de novo synthesis.

[0266] Compound 1 (which was also the most active ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of thyroid beta-agonist and particularly discloses application of agonist in treatment of X-interlinking adrenoleukodystrophy. The method comprising administering to a subject a compound having a structure, or a salt, ester, or prodrug of the compound.

Description

[0001] This application is a PCT international application PCT / US2017 / 029102 submitted on April 24, 2017, which entered the Chinese national phase on December 21, 2018. The Chinese patent application number is 201780038675.7, and the title of the invention is "Application of thyroid beta-agonists" The divisional application of the invention patent application. [0002] related application [0003] This application claims the benefit of priority to U.S. Provisional Patent Application Serial No. 62 / 326,431, filed April 22, 2016. This application is hereby incorporated by reference in its entirety. technical field [0004] The present invention relates to methods for the treatment of X-linked adrenoleukodystrophy. Background technique [0005] Adrenoleukodystrophy (also known as X-linked adrenoleukodystrophy, X-ALD) is a disorder of peroxisome fatty acid beta oxidation, which results in the accumulation of very long chain fatty acids in tissues throughout the body . The mos...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/662A61K31/665A61P25/28
CPCA61K31/662A61K31/665A61P25/28A61P5/14
Inventor B·连R·汉利M·迪纳曼
Owner VIKING THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com